Mezagitamab

Phase 3Monoclonal antibody

Takeda

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Immune Thrombocytopenic Purpura ( ITP )Recruiting

Immune Thrombocytopenic Purpura ( ITP )Phase 3

Recruiting

Timeline

Expected Milestones

Q1 2028

Phase 3Recruiting

Immune Thrombocytopenic Purpura ( ITP )

NCT06722235

Q1 2029

Phase 2Not yet recruiting

Antibody-Mediated Rejection

NCT07613359

Q3 2029

Phase 3Recruiting

Immune Thrombocytopenic Purpura ( ITP )

NCT06948318

Q1 2030

Phase 3Recruiting

Kidney Disease

NCT06963827

Clinical

Trials by Indication[1]

Multiple Myeloma2 trials

A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)

Terminated· Takeda logo

Takeda·Phase 1/2·NCT04776018·27 enrolled

A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)

Completed· Takeda logo

Takeda·Phase 1/2·NCT03439280·50 enrolled

Immune Thrombocytopenic Purpura ( ITP )2 trials

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants With Chronic Primary Immune Thrombocytopenia

Recruiting· Takeda logo

Takeda·Phase 3·NCT06722235·171 enrolled

A Phase 3, Open-label, Multicenter Continuation Trial to Evaluate the Long-term Safety and Efficacy of Mezagitamab Subcutaneous Injection in Adults With Chronic Primary Immune Thrombocytopenia

Recruiting· Takeda logo

Takeda·Phase 3·NCT06948318·150 enrolled

Nephropathy1 trial

A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy

Completed· Takeda logo

Takeda·Phase 1·NCT05174221·17 enrolled

Kidney Disease1 trial

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate Efficacy and Safety of Mezagitamab (TAK-079) in Study Participants With Primary IgA Nephropathy in Combination With Stable Background Therapy

Recruiting· Takeda logo

Takeda·Phase 3·NCT06963827·347 enrolled

Antibody-mediated Rejection1 trial

A Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase 2 Trial to Evaluate the Safety and Efficacy of Mezagitamab (TAK-079) in Kidney Transplant Recipients With Late Antibody-Mediated Rejection (AMR)

Not yet recruiting· Takeda logo

Takeda·Phase 2·NCT07613359·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Mezagitamab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mezagitamab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mezagitamab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: Takeda

Mezagitamab

Status by Indication[3][1]

Expected Milestones

Q1 2028

Q1 2029

Q3 2029

Q1 2030

Trials by Indication[1]

Multiple Myeloma2 trials

Immune Thrombocytopenic Purpura ( ITP )2 trials

Nephropathy1 trial

Kidney Disease1 trial

Antibody-mediated Rejection1 trial

References

Drug Info

Quick Facts

Related News